Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) FCF Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed FCF Margin for 5 consecutive years, with 129.49% as the latest value for Q3 2025.

  • Quarterly FCF Margin rose 38828.0% to 129.49% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 832.78% through Dec 2025, down 41558.0% year-over-year, with the annual reading at 832.78% for FY2025, 41558.0% down from the prior year.
  • FCF Margin for Q3 2025 was 129.49% at Janux Therapeutics, up from 517.77% in the prior quarter.
  • The five-year high for FCF Margin was 1462.89% in Q1 2021, with the low at 1479.09% in Q2 2023.
  • Average FCF Margin over 5 years is 528.91%, with a median of 591.08% recorded in 2021.
  • The sharpest move saw FCF Margin tumbled -224911bps in 2022, then soared 136867bps in 2024.
  • Over 5 years, FCF Margin stood at 687.5% in 2021, then grew by 12bps to 603.48% in 2022, then surged by 41bps to 353.43% in 2023, then plummeted by -46bps to 517.77% in 2024, then soared by 75bps to 129.49% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 129.49%, 517.77%, and 110.42% for Q3 2025, Q3 2024, and Q2 2024 respectively.